GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Other Operating Expense

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Other Operating Expense : $0.23 Mil (TTM As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Other Operating Expense?

Cotinga Pharmaceuticals's Other Operating Expense for the three months ended in Jan. 2020 was $0.02 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2020 was $0.23 Mil.

Cotinga Pharmaceuticals's quarterly Other Operating Expense declined from Jul. 2019 ($0.02 Mil) to Oct. 2019 ($0.01 Mil) but then increased from Oct. 2019 ($0.01 Mil) to Jan. 2020 ($0.02 Mil).

Cotinga Pharmaceuticals's annual Other Operating Expense increased from Apr. 2017 ($-0.11 Mil) to Apr. 2018 ($0.14 Mil) and increased from Apr. 2018 ($0.14 Mil) to Apr. 2019 ($0.19 Mil).


Cotinga Pharmaceuticals Other Operating Expense Historical Data

The historical data trend for Cotinga Pharmaceuticals's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Other Operating Expense Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Other Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.11 -0.09 -0.11 0.14 0.19

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 0.18 0.02 0.01 0.02

Cotinga Pharmaceuticals Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Jan. 2020 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cotinga Pharmaceuticals Other Operating Expense Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019